Quality of life (QOL) outcomes with cediranib/placebo in combination with carboplatin/paclitaxel (CP) in advanced non-small cell lung cancer (ANSCLC): results from NCIC CTG BR.24

被引：0
|
作者：
Lee, Christopher W. [1 ]
Ding Keyue [2 ]
Le Maitre, Aurelie [2 ]
Han, Lei [2 ]
Laurie, Scott A. [3 ]
Goss, Glen [3 ]
Shepherd, Frances A. [4 ]
Arnold, Andrew [5 ]
Frymire, Eliot [2 ]
Seymour, Lesley [2 ]
机构：
[1] BC Canc Agcy, Surrey, BC, Canada
[2] NCIC Clin Trials Grp, Kingston, ON, Canada
[3] Ottawa Hosp, Reg Canc Ctr, Ottawa, ON, Canada
[4] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[5] Juravinski Canc Ctr, Hamilton, ON, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S288 / S288
页数：1
相关论文
共 50 条
  • [1] Gemcitabine-paclitaxel-carboplatin (PCG) versus paclitaxel-carboplatin (PC) in advanced non-small cell lung cancer (NSCLC): Quality of life (QOL) analysis
    Oniga, F.
    Paccagnella, A.
    Luise, A.
    Biason, R.
    Ghi, M. G.
    Gatti, C.
    Nascimben, O.
    Mastromauro, C.
    Medici, M.
    D'Amanzo, P.
    Carnuccio, R.
    McMahon, L.
    ANNALS OF ONCOLOGY, 2006, 17 : XI19 - XI19
  • [2] Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
    Laurie, S. A.
    Solomon, B. J.
    Seymour, L.
    Ellis, P. M.
    Goss, G. D.
    Shepherd, F. A.
    Boyer, M. J.
    Arnold, A. M.
    Clingan, P.
    Laberge, F.
    Fenton, D.
    Hirsh, V.
    Zukin, M.
    Stockler, M. R.
    Lee, C. W.
    Chen, E. X.
    Montenegro, A.
    Ding, K.
    Bradbury, P. A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (04) : 706 - 712
  • [3] Meloxicam in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer
    Takahashi, T
    Ueda, S
    Kogure, Y
    Ebisawa, M
    Asai, G
    Yamamoto, N
    LUNG CANCER, 2005, 49 : S271 - S271
  • [4] Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
    Goss, Glenwood D.
    Arnold, Andrew
    Shepherd, Frances A.
    Dediu, Mircea
    Ciuleanu, Tudor-Eliade
    Fenton, David
    Zukin, Mauro
    Walde, David
    Laberge, Francis
    Vincent, Mark D.
    Ellis, Peter M.
    Laurie, Scott A.
    Ding, Keyue
    Frymire, Eliot
    Gauthier, Isabelle
    Leighl, Natasha B.
    Ho, Cheryl
    Noble, Jonathan
    Lee, Christopher W.
    Seymour, Lesley
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 49 - 55
  • [5] Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel
    Resende Avelino, Camila Uanne
    Cardoso, Rafael Marques
    de Aguiar, Suzana Sales
    Sobreira da Silva, Mario Jorge
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2015, 41 (02) : 133 - 142
  • [6] Overall survival [OS] results of NCIC Clinical Trials Group [CTG] BR.24: a randomized, double-blind trial of carboplatin plus paclitaxel [C plus P] with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced non-small cell lung cancer [NSCLC]
    Laurie, Scott A.
    Arnold, Andrew
    Shepherd, Frances A.
    Dediu, Mircea
    Ciuleanu, Tudor
    Fenton, David
    Zukin, Mauro
    Goss, Glenwood
    Ding, Keyue
    Seymour, Lesley
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S353 - S353
  • [7] Biweekly combination chemotherapy with paclitaxel and carboplatin for advanced non-small cell lung cancer.
    Takayama, K
    Ichiki, M
    Kawasaki, M
    Ninomiya, K
    Miyazaki, N
    Kuba, M
    Iwami, F
    Nakanishi, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 699S - 699S
  • [8] BRM PROMOTER VARIANTS AND SURVIVAL OUTCOMES OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS: A VALIDATION STUDY IN THE NCIC CLINICAL TRIALS GROUP (NCIC-CTG) BR24 CLINICAL TRIAL
    Cuffe, Sinead
    Cheng, Lu
    Azad, Abul K.
    Brhane, Yonathan
    Cheng, Dangxiao
    Chen, Zhuo
    Qiu, Xin
    Boyd, Kevin
    Leighl, Natasha
    Xu, Wei
    Chen, Bingshu E.
    Bradbury, Penelope
    Shepherd, Frances A.
    Seymour, Lesley
    Tsao, Ming S.
    Reisman, David N.
    Liu, Geoffrey
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S132 - S133
  • [9] Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
    Goss, Glenwood D.
    O'Callaghan, Chris
    Lorimer, Ian
    Tsao, Ming-Sound
    Masters, Gregory A.
    Jett, James
    Edelman, Martin J.
    Lilenbaum, Rogerio
    Choy, Hak
    Khuri, Fadlo
    Pisters, Katherine
    Gandara, David
    Kernstine, Kemp
    Butts, Charles
    Noble, Jonathan
    Hensing, Thomas A.
    Rowland, Kendrith
    Schiller, Joan
    Ding, Keyue
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) : 3320 - +
  • [10] Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer
    Ramalingam, Suresh S.
    Blais, Normand
    Mazieres, Julien
    Reck, Martin
    Jones, C. Michael
    Juhasz, Erzsebet
    Urban, Laszlo
    Orlov, Sergey
    Barlesi, Fabrice
    Kio, Ebenezer
    Keiholz, Ulrich
    Qin, Qin
    Qian, Jiang
    Nickner, Caroline
    Dziubinski, Juliann
    Xiong, Hao
    Ansell, Peter
    McKee, Mark
    Giranda, Vincent
    Gorbunova, Vera
    CLINICAL CANCER RESEARCH, 2017, 23 (08) : 1937 - 1944
12345